British Columbia Drug and Poison Information Centre (BC DPIC)

282 MEP have been discontinued (sales ceased 30 July 2013) and the DIN will be cancelled effective 28 October 2013. Health Canada has evaluated information on the risk of overdose/abuse/misuse in patients treated with this medication. Meprobamate has a narrow therapeutic index and may cause serious adverse events (including overdose, loss of consciousness, abuse, pharmacodependence and withdrawal symptoms), even under normal conditions of use. Since the approval of meprobamate, other medications (e.g., muscle relaxants, anxiolytics, antidepressants) have largely displaced the use of meprobamate in Canada and in other countries. Taking this new safety information and the available efficacy data into account, Health Canada has concluded that the risks of 282 MEP® outweigh the benefits under normal conditions of use.